HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Zhou, H. Search for Related Content PubMed PubMed Citation Articles by Zhou, H. Social Bookmarking                         What's this?

Clinical Pharmacokinetics of Etanercept: A Fully Humanized Soluble Recombinant Tumor Necrosis Factor Receptor Fusion Protein

From Clinical Pharmacology, Wyeth Pharmaceticals, Collegeville, Pennsylvania.

Etanercept, a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein, is an approved treatment for rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis. Etanercept is absorbed slowly from the site of subcutaneous injection, with time to peak concentration at approximately 48 to 60 hours, and is cleared slowly from the body with a t_1/2 of 70 to 100 hours. The absolute bioavailability of etanercept was 58% in healthy subjects following subcutaneous administration. The 25-mg twice-weekly dosage regimen generates systemic exposures comparable to 50 mg once weekly, as predicted by pharmacokinetic modeling and simulation and later confirmed by clinical studies. The pharmacokinetics of etanercept in patients with rheumatoid arthritis are comparable to those in healthy individuals and patients with ankylosing spondylitis, congestive heart failure, and psoriasis. In children with polyarticular-course juvenile rheumatoid arthritis, after subcutaneous doses of 0.4 mg/kg twice weekly, the clearance of etanercept may be slightly reduced in children aged 4 to 8 years. Pharmacokinetic simulation predicts that a dose of 0.8 mg/kg once weekly generates comparable systemic exposure as 0.4 mg/kg twice weekly. No requirement for etanercept dosage adjustment is needed when etanercept is coadministered with warfarin, digoxin, or methotrexate.

Key Words: Etanercept • pharmacokinetics

Address for reprints: Honghui Zhou, PhD, FCP, Clinical Pharmacology, Wyeth Pharmaceuticals, Collegeville, PA 19426.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M K de Vries, I E van der Horst-Bruinsma, M T Nurmohamed, L A Aarden, S O Stapel, M J L Peters, J C van Denderen, B A C Dijkmans, and G J Wolbink Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis Ann Rheum Dis, April 1, 2009; 68(4): 531 - 535. [Abstract] [Full Text] [PDF]

				S. Kawai, H. Sekino, N. Yamashita, S. Tsuchiwata, H. Liu, and J. M. Korth-Bradley The comparability of etanercept pharmacokinetics in healthy Japanese and american subjects. J. Clin. Pharmacol., April 1, 2006; 46(4): 418 - 423. [Abstract] [Full Text] [PDF]